![](https://wp-static.smartkarma.com/../assets/uploaded/2022/10/DailyBriefHealthCareBionoteSDBiosensorBloomageBiotechnologyCorporationAandmore.jpg)
In today’s briefing:
- BioNote IPO Preview
- SD Biosensor (137310 KS): Aggressively Investing Windfall Gain From COVID; Adding New Growth Engines
- Bloomage Biotechnology (688363.CH) – Positioning and Strategic Layout Imply Strong Upside Potential
BioNote IPO Preview
- BioNote, a Korean company specializing in bio contents and animal diagnostics, is getting ready for an IPO in November.
- The IPO price range is from 18,000 won to 22,000 won per share. The IPO offering amount is from 234 billion won to 286 billion won.
- At the high end of IPO price, its market cap would be 2.3 trillion won. Using annualized net profit of 597 billion won, this would suggest a P/E of 3.9x.
SD Biosensor (137310 KS): Aggressively Investing Windfall Gain From COVID; Adding New Growth Engines
- In July 2022, SD Biosensor (137310 KS) in partnership with SJL Partners signed a definitive merger agreement to acquire Meridian Bioscience (VIVO US) for approximately KRW800 billion (~$1.5 billion).
- The acquisition will strengthen SD Biosensos’s IVD platform to navigate the decline in COVID-19 testing demand and accelerate its U.S. market entry.
- In September 2021, SD Biosensor acquired ~22% stake in UXN, which aims to launch mini continuous blood glucose meter in domestic market in 2024.
Bloomage Biotechnology (688363.CH) – Positioning and Strategic Layout Imply Strong Upside Potential
- Many interpretations of Bloomage are just looking at the surface of the Company. It is actually a biotechnology and biomaterial company, with business layout covering the whole industrial chain.
- The biggest advantage is the innovation of raw materials.Based on synthetic biology, Bloomage is more comfortable in the richness of raw materials (hyaluronic acid/collagen etc.) and flexibility of product matrix expansion.
- The synergy/complementarity of multiple businesses improve the resilience to market/policy changes. If investors cannot have a deep understanding of Bloomage’s positioning/real strategic intentions, they won’t seize the alpha in the future.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars